Monte Rosa Therapeutics, Inc. (GLUE) Tops Q3 EPS by 2c

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) reported Q3 EPS of ($0.70), $0.02 better than the analyst estimate of ($0.72).

For earnings history and earnings-related data on Monte Rosa Therapeutics, Inc. (GLUE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c